Literature DB >> 28488392

Risk factors for locoregional relapse after radical nephrectomy.

Sameer Jhavar1, Gregory Swanson1, Jessica Pruszynski2.   

Abstract

AIM: To identify risk factors for locoregional relapse after radical nephrectomy for renal cell carcinoma.
METHODS: We retrospectively reviewed the charts of 259 patients who underwent radical nephrectomy for sporadic clinically localized unilateral renal cell carcinoma between 1998 and 2012. Relapse patterns (locoregional and/or distant) were identified. Relapse-free survival was calculated using Kaplan-Meier method. Factors associated with decreased relapse-free survival were identified using univariate and multivariate Cox proportional hazards regression model analysis. Locoregional relapse estimates were calculated for individual factors and combination of factors.
RESULTS: At a median follow-up of 68 months (interquartile range: 75 months), 24% patients relapsed. Of these, 54% had locoregional relapse. High-grade, positive margin, large tumor size and stage III/IV were associated with worse relapse-free survival on multivariate analysis. Locoregional relapse occurred among patients with tumor size >7-</ = 10 cm (22%), >10 cm (35%), stage III/IV (31%), grade III/IV (26%), renal vein invasion (22%), perinephric fat invasion (30%), </ = 7 cm plus grade III/IV (15%), >7 cm plus grade I/II (21%), >7 cm plus grade III/IV (48%), stage III/IV plus grade I/II (24%) and stage III/IV plus grade III/IV (45%).
CONCLUSION: We were able to discern risk factors (individual or in combination) associated with increased risk of locoregional relapse after radical nephrectomy for renal cell carcinoma. This could help distinguish patients who may benefit from adjuvant locoregionally directed therapy.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  grade; locoregional relapse; radical nephrectomy; renal cell carcinoma; size

Mesh:

Year:  2017        PMID: 28488392     DOI: 10.1111/ajco.12684

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  2 in total

1.  Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.

Authors:  Ana Elena Martín-Aguilar; Haidé Núñez-López; Juan C Ramirez-Sandoval
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

2.  Risk Factors and Patterns of Locoregional Recurrence after Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma.

Authors:  Gyu Sang Yoo; Won Park; Hongryull Pyo; Byong Chang Jeong; Hwang Gyun Jeon; Minyong Kang; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi; Byung Kwan Park; Chan Kyo Kim; Sung Yoon Park; Ghee Young Kwon
Journal:  Cancer Res Treat       Date:  2021-04-15       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.